1 |
Zafari N, Bathaei P, Velayati M, Khojasteh-Leylakoohi F, Khazaei M, Fiuji H, Nassiri M, Hassanian SM, Ferns GA, Nazari E, Avan A. Integrated analysis of multi-omics data for the discovery of biomarkers and therapeutic targets for colorectal cancer. Comput Biol Med 2023;155:106639. [PMID: 36805214 DOI: 10.1016/j.compbiomed.2023.106639] [Reference Citation Analysis]
|
2 |
Dai X, Zeng M, Huang Z, Zhang J, Wei Z, Wang Z. A Novel Prognostic Chemokine-Related lncRNAs Signature Associated with Immune Landscape in Colon Adenocarcinoma. Disease Markers 2022;2022:1-38. [DOI: 10.1155/2022/2823042] [Reference Citation Analysis]
|
3 |
Zhang Y, Zhang K, Gong H, Li Q, Man L, Jin Q, Zhang L, Li S. Links Between N6-Methyladenosine and Tumor Microenvironments in Colorectal Cancer. Front Cell Dev Biol 2022;10:807129. [DOI: 10.3389/fcell.2022.807129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
4 |
Liu W, Liu C, Wang H, Xu L, Zhou J, Li S, Cheng Y, Zhou R, Zhao L. Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy. Computational and Structural Biotechnology Journal 2022;20:5150-61. [DOI: 10.1016/j.csbj.2022.09.017] [Reference Citation Analysis]
|